MX2020012245A - Sindrome de choque toxico estreptococico. - Google Patents
Sindrome de choque toxico estreptococico.Info
- Publication number
- MX2020012245A MX2020012245A MX2020012245A MX2020012245A MX2020012245A MX 2020012245 A MX2020012245 A MX 2020012245A MX 2020012245 A MX2020012245 A MX 2020012245A MX 2020012245 A MX2020012245 A MX 2020012245A MX 2020012245 A MX2020012245 A MX 2020012245A
- Authority
- MX
- Mexico
- Prior art keywords
- shock syndrome
- toxic shock
- protein
- streptococcal toxic
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporcionan en la presente métodos para inmunizar, tratar o prevenir el síndrome de choque tóxico estreptocócico en un sujeto, mediante la administración de una proteína M de estreptococo del grupo A, que incluye fragmentos, variantes o derivados de la misma, o un anticuerpo que se une o se genera contra la proteína M y, opcionalmente, una proteína superantígeno de estreptococo del grupo A, que incluye fragmentos, variantes o derivados de la misma, o un anticuerpo o fragmento de anticuerpo que se une, o se genera contra, la proteína superantígeno.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2018901709A AU2018901709A0 (en) | 2018-05-16 | Streptococcal toxic shock syndrome | |
AU2018904377A AU2018904377A0 (en) | 2018-11-16 | Streptococcal toxic shock syndrome | |
PCT/AU2019/050469 WO2019218022A1 (en) | 2018-05-16 | 2019-05-16 | Streptococcal toxic shock syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020012245A true MX2020012245A (es) | 2021-01-29 |
Family
ID=68539133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020012245A MX2020012245A (es) | 2018-05-16 | 2019-05-16 | Sindrome de choque toxico estreptococico. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210292398A1 (es) |
EP (1) | EP3806896A4 (es) |
JP (1) | JP2021523908A (es) |
KR (1) | KR20210010882A (es) |
CN (1) | CN112449603A (es) |
AU (1) | AU2019268417A1 (es) |
BR (1) | BR112020023128A2 (es) |
CA (1) | CA3100212A1 (es) |
MX (1) | MX2020012245A (es) |
SG (1) | SG11202011348YA (es) |
WO (1) | WO2019218022A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4214230A1 (en) * | 2020-09-18 | 2023-07-26 | Tanea Medical AB | Antibodies against streptococcal m protein |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998024910A2 (en) * | 1996-12-06 | 1998-06-11 | Regents Of The University Of Minnesota | Mutants of streptococcal toxin c and methods of use |
DE69737032D1 (de) * | 1996-12-06 | 2007-01-11 | Univ Minnesota | Mutanten von streptococcaltoxinen und vefahren zu deren anwendung |
US6075119A (en) * | 1997-04-07 | 2000-06-13 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome |
US20050010034A1 (en) * | 1997-12-05 | 2005-01-13 | Regents Of The University Of Minnesota | Mutants of streptococcal toxin C and methods of use |
ATE557041T1 (de) * | 2001-05-18 | 2012-05-15 | Us Gov Health & Human Serv | Peptid-vakzinen gegen streptokokken der gruppe a |
US20090010929A1 (en) * | 2006-12-04 | 2009-01-08 | Good Michael F | Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates |
US20090162369A1 (en) * | 2007-12-12 | 2009-06-25 | Katin Helena Threse Nordstrom | Synthetic chimeric peptides |
-
2019
- 2019-05-16 EP EP19803402.7A patent/EP3806896A4/en active Pending
- 2019-05-16 BR BR112020023128-2A patent/BR112020023128A2/pt unknown
- 2019-05-16 SG SG11202011348YA patent/SG11202011348YA/en unknown
- 2019-05-16 MX MX2020012245A patent/MX2020012245A/es unknown
- 2019-05-16 CA CA3100212A patent/CA3100212A1/en active Pending
- 2019-05-16 CN CN201980047414.0A patent/CN112449603A/zh active Pending
- 2019-05-16 KR KR1020207035598A patent/KR20210010882A/ko not_active Application Discontinuation
- 2019-05-16 US US17/055,294 patent/US20210292398A1/en active Pending
- 2019-05-16 WO PCT/AU2019/050469 patent/WO2019218022A1/en active Application Filing
- 2019-05-16 AU AU2019268417A patent/AU2019268417A1/en active Pending
- 2019-05-16 JP JP2020564062A patent/JP2021523908A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210010882A (ko) | 2021-01-28 |
JP2021523908A (ja) | 2021-09-09 |
BR112020023128A2 (pt) | 2021-02-02 |
AU2019268417A1 (en) | 2020-12-03 |
EP3806896A1 (en) | 2021-04-21 |
CA3100212A1 (en) | 2019-11-21 |
CN112449603A (zh) | 2021-03-05 |
SG11202011348YA (en) | 2020-12-30 |
WO2019218022A1 (en) | 2019-11-21 |
US20210292398A1 (en) | 2021-09-23 |
EP3806896A4 (en) | 2022-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2024008677A (es) | Conjugados de camptotecina. | |
EP3689909A4 (en) | Tigit antibody, antigen-binding fragment thereof, and medical use thereof | |
ZA201904218B (en) | Anti¿ccr7 antibody drug conjugates | |
EP4344706A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
EA201991157A1 (ru) | Доставка белков на основе бактерий, аттенуированных по вирулентности | |
JO3559B1 (ar) | جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه | |
TW201613575A (en) | Treatment of polybacterial infections | |
MX2019015516A (es) | Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer. | |
EP3882268A4 (en) | ANTI-CD73 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION THEREOF | |
MX2021002910A (es) | Vacunas neumococicas multivalentes. | |
EP3712170A4 (en) | CD96 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF | |
IL275798A (en) | Methods for antibody drug conjugation, purification and formulation | |
MX2021004173A (es) | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. | |
MX2019011624A (es) | Metodos y composiciones para la reduccion de la inmunogenicidad. | |
ZA202206993B (en) | Anti-lilrb1 antibody and uses thereof | |
WO2017075188A3 (en) | Methods of using anti-alpha toxin antibody | |
EP4079760A3 (en) | Antibodies against clostridium difficile toxins and methods of using the same | |
MX2021009105A (es) | Toxinas apxia, apxiia y apxiiia inactivadas. | |
WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use | |
MX2019009546A (es) | Anticuerpos anti-factor d y uso de los mismos. | |
EP3587452A4 (en) | ANTI-TIM-3 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF IT, AND MEDICAL USES OF IT | |
WO2018027124A8 (en) | ANTI-O2 ANTIBODIES AND USES THEREOF | |
WO2016145385A3 (en) | Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails | |
MX2023002805A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos. | |
EP3919516A4 (en) | ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF |